onclive· 2mo ago
save<![CDATA[Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEA]]>
May 7, 2026read original ↗
<![CDATA[Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.]]>
Full text isn't available here yet — read it at onclive.
read full article on onclive ↗🔗 mentioned in this article
no entities indexed yet
comments(0)
5-min edit window · permanent after that